I.M. Holdaway, M.J. Bollard, G.D. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159, 89–95 (2008). https://doi.org/10.1530/EJE-08-0267
Article CAS PubMed Google Scholar
S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanuela, J.A.H. Wass, C.J. Strasburger, A. Luger, D.R. Clemmons, A. Giustina, A Consensus Statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552–561 (2011). https://doi.org/10.1038/s41574-018-0058-5
M.R. Gadelha, L.E. Wildemberg, M.D. Bronstein, F. Gatto, D. Ferone, Somatostatin receptor ligands in the treatment of acromegaly. Pituitary 20, 100–108 (2018)
A. Colao, R.S. Auriemma, G. Lombardi, R. Pivonello, Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32(2), 247–271 (2011). https://doi.org/10.1210/er.2010-0002
Article CAS PubMed Google Scholar
A. Giustina, G. Barkhoudarian, A. Beckers, A. Ben-Shlomo, N. Biermasz, B. Biller, C. Boguszewski, M. Bolanowski, J. Bollerslev, V. Bonert, M.D. Bronstein, M. Buchfelder, F. Casanueva, P. Chanson, D. Clemmons, M. Fleseriu, A.M. Formenti, P. Freda, M. Gadelha, E. Geer, M. Gurnell, A.P. Heaney, K.K.Y. Ho, A.G. Ioachimescu, S. Lamberts, E. Laws, M. Losa, P. Maffei, A. Mamelak, M. Mercado, M. Molitch, P. Mortini, A.M. Pereira, S. Petersenn, K. Post, M. Puig-Domingo, R. Salvatori, S.L. Samson, I. Shimon, C. Strasburger, B. Swearingen, P. Trainer, M.L. Vance, J. Wass, M.E. Wierman, K.C.J. Yuen, M.C. Zatelli, S. Melmed, Multidisciplinary management of acromegaly: A consensus. Rev. Endocr. Metab. Disord. 21(4), 667–678 (2020). https://doi.org/10.1007/s11154-020-09588-z
Article PubMed PubMed Central Google Scholar
M. Fleseriu, B.M.K. Biller, P.U. Freda, M.R. Gadelha, A. Giustina, L. Katznelson, M.E. Molitch, S.L. Samson, C.J. Strasburger, A.J. van der Lely, S. Melmed, A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1), 1–13 (2021). https://doi.org/10.1007/s11102-020-01091-7
R. Cozzi, M.R. Ambrosio, R. Attanasio, A. Bozzao, L. De Marinis, E. De Menis, E. Guastamacchia, A. Lania, G. Lasio, F. Logoluso, P. Maffei, M. Poggi, V. Toscano, M. Zini, P. Chanson, L. Katznelson, Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues. Endocr. Metab. Immune Disord. Drug Targets 20(8), 1144–1155 (2020). https://doi.org/10.2174/1871530320666200129113328
S. Chiloiro, A. Bianchi, F. Doglietto, C. de Waure, A. Giampietro, A. Fusco, D. Iacovazzo, L. Tartaglione, F. Di Nardo, S. Chiloiro, A. Bianchi, F. Doglietto, C. de Waure, A. Giampietro, A. Fusco, D. Iacovazzo, L. Tartaglione, F. Di Nardo, F. Signorelli, L. Lauriola, C. Anile, G. Maira, L. De Marinis, Radically resected pituitary adenomas: Prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature. Pituitary 17(3), 267–276 (2014). https://doi.org/10.1007/s11102-013-0500-6
A. Muhammad, E.C. Coopmans, F. Gatto, S.E. Franck, J.A.M.J.L. Janssen, A.J. van der Lely, L.J. Hofland, S.J.C.M.M. Neggers, Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression. J. Clin. Endocrinol. Metab. 104(3), 915–924 (2019). https://doi.org/10.1210/jc.2018-01524
D. Iacovazzo, E. Carlsen, F. Lugli, S. Chiloiro, S. Piacentini, A. Bianchi, A. Giampietro, M. Mormando, A.J. Clear, F. Doglietto, C. Anile, G. Maira, L. Lauriola, G. Rindi, F. Roncaroli, A. Pontecorvi, M. Korbonits, L. De Marinis, Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study. Eur. J. Endocrinol. 174(2), 241–250 (2016). https://doi.org/10.1530/EJE-15-0832
Article CAS PubMed Google Scholar
S. Grozinsky-Glasberg, I. Shimon, M. Korbonits, A.B. Grossman, Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr. Relat. Cancer 15(3), 701–720 (2008). https://doi.org/10.1677/ERC-07-0288
Article CAS PubMed Google Scholar
C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, G. Weckbecker, SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146(5), 707–716 (2002). https://doi.org/10.1530/eje.0.1460707
Article CAS PubMed Google Scholar
A. Bianchi, F. Valentini, R. Iuorio, M. Poggi, R. Baldelli, M. Passeri, A. Giampietro, L. Tartaglione, S. Chiloiro, M. Appetecchia, P. Gargiulo, A. Fabbri, V. Toscano, A. Pontecorvi, L. De Marinis, Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J. Exp. Clin. Cancer Res. 32(1), 40 (2013). https://doi.org/10.1186/1756-9966-32-40
Article CAS PubMed PubMed Central Google Scholar
P.J. Trainer, W.M. Drake, L. Katznelson, P.U. Freda, V. Herman-Bonert, A.J. van der Lely, E.V. Dimaraki, P.M. Stewart, K.E. Friend, M.L. Vance, G.M. Besser, J.A. Scarlett, M.O. Thorner, C. Parkinson, A. Klibanski, J.S. Powell, A.L. Barkan, M.C. Sheppard, M. Malsonado, D.R. Rose, D.R. Clemmons, G. Johannsson, B.A. Bengtsson, S. Stavrou, D.L. Kleinberg, D.M. Cook, L.S. Phillips, M. Bidlingmaier, C.J. Strasburger, S. Hackett, K. Zib, W.F. Bennett, R.J. Davis, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342(16), 1171–1177 (2000). https://doi.org/10.1056/NEJM200004203421604
A.J. van der Lely, R.K. Hutson, P.J. Trainer, G.M. Besser, A.L. Barkan, L. Katznelson, A. Klibanski, V. Herman-Bonert, S. Melmed, M.L. Vance, P.U. Freda, P.M. Stewart, K.E. Friend, D.R. Clemmons, G. Johannsson, S. Stavrou, D.M. Cook, L.S. Phillips, C.J. Strasburger, S. Hackett, K.A. Zib, R.J. Davis, J.A. Scarlett, M.O. Thorner, Long term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 24(358(9295)), 1754–1759 (2001). https://doi.org/10.1016/s0140-6736(01)06844-1
J. Feenstra, W.W. de Herder, S.M. ten Have, A.W. van den Beld, R.A. Feelders, J.A. Janssen, A.J. van der Lely, Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 13(365(9471)), 1644–1646 (2005). https://doi.org/10.1016/S0140-6736(05)63011-5
J.O. Jørgensen, U. Feldt-Rasmussen, J. Frystyk, J.W. Chen, L.Ø. Kristensen, C. Hagen, H. Ørskov, Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J. Clin. Endocrinol. Metab. 90(10), 5627–5631 (2005). https://doi.org/10.1210/jc.2005-0531
P.J. Trainer, S. Ezzat, G.A. D’Souza, G. Layton, C.J. Strasburger, A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin. Endocrinol. (Oxf.) 71(4), 549–557 (2009). https://doi.org/10.1111/j.1365-2265.2009.03620.x
A.J. van der Lely, I. Bernabeu, J. Cap, P. Caron, A. Colao, J. Marek, S. Neggers, P. Birman, Coadministration of lanreotide Autogel and Pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur. J. Endocrinol. 164(3), 325–333 (2011). https://doi.org/10.1530/EJE-10-0867
M. Filopanti, L. Olgiati, G. Mantovani, S. Corbetta, M. Arosio, V. Gasco, L. De Marinis, C. Martini, F. Bogazzi, S. Cannavò, A. Colao, D. Ferone, G. Arnaldi, F. Pigliaru, A. Peri, G. Angeletti, M.L. Jaffrain-Rea, A.G. Lania, A. Spada, Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J. Clin. Endocrinol. Metab. 97(2), E165–E172 (2012). https://doi.org/10.1210/jc.2011-1769
S. Chiloiro, A. Giampietro, F. Mirra, F. Donfrancesco, T. Tartaglione, P.P. Mattogno, F. Angelini, L. Liverana, M. Gessi, A. Carmelo, G. Rindi, A. Giustina, M. Fleseriu, A. Pontecorvi, L. De Marinis, A. Bianchi, Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur. J. Endocrinol. 184(2), 217–229 (2021). https://doi.org/10.1530/EJE-20-0767
Article CAS PubMed Google Scholar
S. Chiloiro, C. Bima, T. Tartaglione, A. Giampietro, M. Gessi, L. Lauretti, C. Anile, C. Colosimo, G. Rindi, A. Pontecorvi, L. De Marinis, A. Bianchi, Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study. J. Clin. Endocrinol. Metab. 104(11), 5478–5482 (2019). https://doi.org/10.1210/jc.2019-00825
O. Cooper, V. Bonert, N.A. Liu, A.N. Mamelak, Treatment of aggressive pituitary adenoma: a case-based narrative review. Front. Endocrinol. 12, 725014 (2021). https://doi.org/10.3389/fendo.2021.725014
S. Barraud, P. Caron, I. Raingeard, H. Lefebvre, G. Raverot, C. Cortet-Rudelli, R. Desailloud, R. Henocque, Y. Brault, T. Brue, P. Chanson, B. Delemer, S. Barraud, P. Caron, I. Raingeard, H. Lefebvre, G. Raverot, C. Cortet-Rudelli, R. Desailloud, R. Henocque, Y. Brault, T. Brue, P. Chanson, B. Delemer. Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients) Ann Endocrinol (Paris). 2021; 10;S0003-4266(21)00078-0. https://doi.org/10.1016/j.ando.2021.05.004
L. Ma, D. Luo, T. Yang, S. Wu, M. Li, C. Chen, S. Zhou, L. Ma, Y. Wu, Y. Zhou, Y. Cui, Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: A meta-analysis of prospective studies. BMC Endocr. Disord. 20(1), 18 (2020). https://doi.org/10.1186/s12902-020-0545-2
M. Fleseriu, D. Führer-Sakel, A.J. van der Lely, L. De Marinis, T. Brue, J. van der Lans-Bussemaker, J. Hey-Hadavi, C. Camacho-Hubner, M.P. Wajnrajch, S.R. Valluri, A.A. Palladino, R. Gomez, R. Salvatori, More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur. J. Endocrinol. 185(4), 525–538 (2021). https://doi.org/10.1530/EJE-21-0239
Article CAS PubMed PubMed Central Google Scholar
H. Yamaguchi, A. Shimatsu, A. Okayama, T. Sato, Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance. Endocr. J. 67(2), 201–210 (2020). https://doi.org/10.1507/endocrj.EJ19-0266
N.X.G. Basavilbaso, M.C. Ballarino, D. Bruera, O.D. Bruno, A.B. Chervin, K. Danilowicz, P. Fainstein-Day, S.G. Fidalgo, A. Frigeri, M. Glerean, R. Guelman, G. Isaac, D.A. Katz, P. Knoblovits, F. Librandi, M.L. Montes, M.S. Mallea-Gil, M. Manavela, P. Mereshian, D. Moncet, A. Pignatta, A. Rogozinsky, L.R. Sago, M. Servidio, M. Spezzi, G. Stalldecker, J. Tkatch, N.M. Vitale, M. Guitelman, Pegvisomant in acromegaly: a multicenter real-life study in Argentina. Arch. Endocrinol. Metab. 63(4), 320–327 (2019). https://doi.org/10.20945/2359-3997000000160
C.L. Boguszewski, M.K.P. Huayllas, L. Vilar, L.A. Naves, A. Ribeiro-Oliveira Junior, B.S. Soares, M.A. Czepielewski, J. Abucham, S.R. Correa-Silva, M.D. Bronstein, R.S. Jallad, F.G. Duarte, N.R. Musolino, L. Kasuki, M.R. Gadelha, Brazilian multicenter study on pegvisomant treatment in acromegaly. Arch. Endocrinol. Metab. 63(4), 328–336 (2019). https://doi.org/10.20945/2359-3997000000159
M. Buchfelder, A.J. van der Lely, B.M.K. Biller, S.M. Webb, T. Brue, C.J. Strasburger, E. Ghigo, C. Camacho-Hubner, K. Pan, J. Lavenberg, P. Jönsson, J.H. Hey-Hadavi, Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur. J. Endocrinol. 179(6), 419–427 (2018). https://doi.org/10.1530/EJE-18-0616
Article CAS PubMed Google Scholar
I. Bernabeu, A. Pico, E. Venegas, J. Aller, C. Alvarez-Escolá, J.A. García-Arnés, M. Marazuela, P. Jonsson, N. Mir, M. García Vargas, Spanish ACROSTUDY Group, Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary 19(2), 127–137 (2016). https://doi.org/10.1007/s11102-015-0691-0
Article CAS PubMed Google Scholar
P. Witek, M. Bolanowski, K. Szamotulska, A. Wojciechowska-Luźniak, A. Jawiarczyk-Przybyłowska, M. Kałużny, The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings. Front Endocrinol. (Lausanne) 12, 633944 (2021). https://doi.org/10.3389/fendo.2021.633944
A. Akirov, A. Gorshtein, I. Dotan, N.S. Khazen, Y. Pauker, M. Gershinsky, I. Shimon, Long-term safety and efficacy of long-acting pasireotide in acromegaly. Endocrine 74(2), 396–403 (2021). https://doi.org/10.1007/s12020-021-02782-2
Article CAS PubMed Google Scholar
I. Shimon, Z. Adnan, A. Gorshtein, L. Baraf, N. Saba Khazen, M. Gershinsky, Y. Pauker, A. Abid, M.J. Niven, C. Shechner, Y. Greenman, Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 62(2), 448–455 (2018). https://doi.org/10.1007/s12020-018-1690-5
Article CAS PubMed Google Scholar
M.D. Bronstein, M. Fleseriu, S. Neggers, A. Colao, M. Sheppard, F. Gu, C.C. Shen, M. Gadelha, A.J. Farrall, K. Hermosillo Reséndiz, M. Ruffin, Y. Chen, P. Freda; Pasireotide C2305 Study Group, Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocr. Disord. 16, 16 (2016). https://doi.org/10.1186/s12902-016-0096-8
Article CAS PubMed PubMed Central Google Scholar
C.J. Strasburger, A. Mattsson, P. Wilton, F. Aydin, J. Hey-Hadavi, B.M.K. Biller, Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist Pegvisomant. Eur. J. Endocrinol. 178(4), 321–329 (2018). https://doi.org/10.1530/EJE-17-0996
Article CAS PubMed PubMed Central Google Scholar
E. Kuhn, P. Caron, B. Delemer, I. Raingeard, H. Lefebvre, G. Raverot, C. Cortet-Rudelli, R. Desailloud, C. Geffroy, R. Henocque, Y. Brault, T. Brue, P. Chanson, Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. Endocrine 71(1), 158–167 (2021). https://doi.org/10.1007/s12020-020-02501
Article CAS PubMed Google Scholar
M. Buchfelder, D. Weigel, M. Droste, K. Mann, B. Saller, K. Brübach, G.K. Stalla, M. Bidlingmaier, C.J. Strasburger, Investigators of German Pegvisomant Observational Study. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur. J. Endocrinol. 161(1), 27–35 (2009). https://doi.org/10.1530/EJE-08-0910
M. Buchfelder, S. Schlaffer, M. Droste, K. Mann, B. Saller, K. Brübach, G.K. Stalla, C.J. Strasbu
留言 (0)